Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)

  • STATUS
    Recruiting
  • End date
    Aug 24, 2026
  • participants needed
    150
  • sponsor
    The Hospital for Sick Children
Updated on 24 January 2021
platelet count
corticosteroids
glomerular filtration rate
BRAF
progressive disease
neutrophil count
vinblastine
auditory test

Summary

This is an open-label, randomized, multi-center, comparator Phase II trial looking at the addition of Bevacizumab to Vinblastine in chemotherapy nave pediatric patients with progressive Low Grade Glioma aged 6 months to less than18 years of age at the time of initiation of therapy. Participants will be randomized to Arm A or Arm B. Arm A includes 68 weeks of single agent Vinblastine administered once weekly IV. Arm B includes 68 weeks of Vinblastine administered weekly IV with the addition of 12 doses of Bevacizumab administered every two weeks IV for the initial 24 weeks. Randomization will take place at the time of registration taking into account NF1 and BRAF-KIAA1549-fusion status.

Details
Condition Low Grade Glioma
Treatment bevacizumab, Vinblastine
Clinical Study IdentifierNCT02840409
SponsorThe Hospital for Sick Children
Last Modified on24 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Children and adolescents aged 6 months to < 18 years old with Low Grade Glioma (See Appendix I)
All patients must submit tumour tissue (fresh tumour tissue is recommended) and have pathological confirmation of LGG and determination of BRAF characteristics from the Hospital for Sick Children. Exceptions will be made for patients with neurofibromatosis type 1 who have not previously had a biopsy. NF1 patients are eligible without tissue confirmation but must have definitive clinical or radiographic evidence of tumour progression or risk for significant neurologic deterioration requiring immediate therapy. If a tissue sample for NF1 patients is available from a previous biopsy, it is required to be submitted for Central Review at the Hospital for Sick Children. Please refer to the lab manual for further details
Patients must have progressive disease following surgical excision based on clear radiological or clinical evidence of progression, or an incomplete excision (< 95% or > 1.0 cm2 residual tumour) with necessity to begin treatment because of a risk of neurological impairment with progression
All patients on study must have measurable tumour (>1.0 cm2 of residual tissue if resection has been performed) within 28 days of enrollment
Patients must have received no prior therapy including chemotherapy, biological modifiers and/or radiation treatment for the tumour with the exception of surgery
Patient is able to start treatment within 14 working days after randomization
Post pubertal teenagers who are sexually active agree to use two methods of contraception during the treatment period and for at least 6 months after the last dose of study drug. Please refer to Appendix V for a list of acceptable methods of contraception
Lansky performance status > 50% for patients < 16 years of age. Karnofsky performance status > 50% for patients 16 years of age
Patients with neurologic deficits must have deficits that are stable for a minimum of 1 week prior to enrollment
Patients receiving corticosteroids must be on a stable or decreasing dose for at least 1 week prior to enrollment
Life expectancy > 2 months at the time of enrollment
Parents/guardians must provide written informed consent and to agree that they (and the patient) will comply with the study protocol
Written assent by patient according to institutional guidelines
Patients must have adequate bone marrow function within 2 weeks prior to enrollment
Hemoglobin 10 g/dL (may be supported )
Neutrophil count 1.0 109/L
Platelet count 100 109/L (transfusion independent)
Patients not on a therapeutic dose of an anti-coagulant must have an INR 1.5 and an aPTT 1.5x institutional ULN for age within 2 weeks prior to enrollment. Anti-coagulation is permitted prior to enrollment on the condition that the patient is, according to the local clinical practice guidelines or approved product labeling, adequately anti-coagulated prior to enrollment
Patients must have satisfactory liver function within 2 weeks prior to enrollment
AST 3x institutional ULN for age
ALT 3x institutional ULN for age
Total Bilirubin 1.5x institutional ULN for age
Patients must have satisfactory renal parameters and meet the following criteria within 2 weeks prior to enrollment
Serum creatinine must be 1.5x ULN for age. If the serum creatinine is > 1.5 ULN, the glomerular filtration rate (either estimated or formal) must be >90 mL/min/1.73 m2, for patient to be enrolled
Absence of clinically significant proteinuria, as defined by screening of the early morning urine (urine protein < 1g/L and/or albumin/creatinine ratio < 1.0 (mg/mmol)). If urine protein 1g/L, then Urine Protein Creatinine (UPC) ratio should be calculated. If UPC ratio > 0.5, 24-hour urine protein should be obtained and the level should be < 1000 mg/24 hours for patient enrollment. Note: UPC ratio of spot urine is an estimation of the 24 urine protein excretion - a UPC ratio of 1 is roughly equivalent to a 24-hour urine protein of 1 g. UPC ratio is calculated using one of the following formulas
[urine protein]/[urine creatinine] - if both protein and creatinine are
reported in mg/dL or [(urine protein) x0.088]/[urine creatinine] - if urine
creatinine is reported in mmol/L
Quality of Life Correlative Study Inclusion Criteria (Optional)
Age 3 and < 18 years
English- or Spanish-speaking
No known history of a significant neurodevelopmental disorder prior to diagnosis of LGG (e.g., Down syndrome, Fragile X, William's Syndrome, mental retardation). Patients with NF1 are not excluded
No significant motor or sensory impairment that would prevent computer use and perception of the visual and auditory test stimuli

Exclusion Criteria

Children under 6 months of age
Pregnant or lactating females
Use of any investigational agent, systemic, targeted or immunotherapy prior to the first dose of study treatment
Any bleeding diathesis or significant coagulopathy at risk of bleeding (i.e. in the absence of therapeutic anticoagulation)
Patients with evidence of new symptomatic CNS hemorrhage (> grade I) on baseline MRI
Any significant cardiovascular disease, e.g. aortic aneurysm requiring surgical repair or recent arterial thrombosis, CVAs, transient ischemic attacks (TIAs), and systemic hypertension (i.e., a systolic and diastolic BP 95th percentile for age, sex), prior history of hypertensive crisis or hypertensive encephalopathy or stroke, uncontrolled cardiac arrhythmia within 6 months prior to enrollment
Any previous venous thromboembolism Grade 3 or higher (NCI CTCAE v. 4.03)
History of abdominal fistula, GI perforation, intra-abdominal abscess or active GI bleeding within 6 months prior to the first study treatment
Unresolved infection
An active peptic or duodenal ulcer
Major surgical procedure (see Table 3 section 6.1.7), brain surgery, open biopsy or significant traumatic injury within 28 days prior to enrollment or the anticipation of the need for major (elective) surgery during the course of the study treatment
Intermediate surgical procedure (see Table 3 section 6.1.7) within 2 weeks of enrollment
Minor surgical procedures (see Table 3 section 6.1.7) within 3 days prior to the start of treatment (including the placement of a central line, including PICC line). Insertion of a port-a-cath will require a 7-day interval prior to the start of treatment
Non-healing surgical wound
A bone fracture that has not satisfactorily healed
Concomitant use of the following
Aspirin (> 325mg/day) within 10 days of enrollment
Clopidogrel (> 75mg/day) within 10 days of enrollment
Use of therapeutic oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes with INR and aPTT outside therapeutic standards according to institutional guidelines within 10 days of first dose of Bevacizumab. Note: The use of full-dose oral or parenteral anticoagulants is permitted as long as the INR or aPTT is within therapeutic limits (according to the medical standard of the institution) and the patient has been on a stable dose of anticoagulants for at least two weeks at the time of the Baseline Visit. Prophylactic use of anticoagulants is allowed
Hypersensitivity to Chinese hamster ovary (CHO) cell products or other recombinant human or humanized antibodies
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note